Johnson & Johnson (NYSE:JNJ) Shares Sold by GYL Financial Synergies LLC

GYL Financial Synergies LLC lowered its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.9% during the third quarter, Holdings Channel.com reports. The fund owned 8,951 shares of the company’s stock after selling 459 shares during the quarter. GYL Financial Synergies LLC’s holdings in Johnson & Johnson were worth $1,462,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD lifted its holdings in Johnson & Johnson by 18.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after purchasing an additional 3,912,430 shares in the last quarter. Legal & General Group Plc lifted its holdings in Johnson & Johnson by 2.3% in the 2nd quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock valued at $3,344,295,000 after purchasing an additional 421,779 shares in the last quarter. FMR LLC lifted its holdings in Johnson & Johnson by 20.8% in the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after purchasing an additional 3,229,032 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Johnson & Johnson by 1.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after purchasing an additional 328,297 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Johnson & Johnson by 0.3% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,163,229 shares of the company’s stock valued at $1,333,545,000 after purchasing an additional 24,505 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Robert J. Decker sold 16,928 shares of Johnson & Johnson stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $175.00, for a total value of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,707,775. The disclosure for this sale can be found here. Insiders sold a total of 233,611 shares of company stock valued at $40,960,735 in the last three months. 0.35% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on JNJ shares. Raymond James decreased their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a report on Wednesday, October 19th. Bank of America reduced their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Credit Suisse Group began coverage on Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target on the stock. StockNews.com began coverage on Johnson & Johnson in a report on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Finally, Barclays began coverage on Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target on the stock. Seven analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $181.75.

Johnson & Johnson Stock Down 0.5 %

Shares of NYSE:JNJ opened at $168.74 on Monday. The business has a 50-day moving average price of $176.14 and a 200 day moving average price of $171.20. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $441.17 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 3.19 and a beta of 0.56. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.68%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.